Dr. Reddy’s launches 2 generics
Dr. Reddy’s is introducing sevelamer carbonate for oral suspension, in 0.8 g and 2.4 g packets, after having received approval from the Food and Drug Administration.
The product is the generic of Sanofi’s Renvela (sevelamer carbonate) for oral suspension. It is used to control phosphorus levels in adults and children 6 years of age and older with chronic kidney disease on dialysis.
The Renvela brand and generic had a market value of roughly $101 million for the most recent twelve months ending in October 2018, according to IQVIA.
Dr. Reddy’s also is introducing aspirin and extended-release dipyridamole capsules, having received the Food and Drug Administration’s nod earlier.
The product is the generic of Boehringer Ingelheim’s Aggrenox (aspirin and extended-release dipyridamole) capsules.
The Aggrenox brand and generic had a market value of about $182 million or the most recent twelve months ending in October 2018, according to IQVIA data.
Dr. Reddy’s product is available in 25 mg/200 mg dosage strengths in a 60- count bottle size.
The product is the generic of Sanofi’s Renvela (sevelamer carbonate) for oral suspension. It is used to control phosphorus levels in adults and children 6 years of age and older with chronic kidney disease on dialysis.
The Renvela brand and generic had a market value of roughly $101 million for the most recent twelve months ending in October 2018, according to IQVIA.
Dr. Reddy’s also is introducing aspirin and extended-release dipyridamole capsules, having received the Food and Drug Administration’s nod earlier.
The product is the generic of Boehringer Ingelheim’s Aggrenox (aspirin and extended-release dipyridamole) capsules.
The Aggrenox brand and generic had a market value of about $182 million or the most recent twelve months ending in October 2018, according to IQVIA data.
Dr. Reddy’s product is available in 25 mg/200 mg dosage strengths in a 60- count bottle size.